CNS Biomarkers Market Companies Ecosystem Overview
Tier 1 Leaders
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific
- GE HealthCare
- Siemens Healthineers
These companies dominate the CNS biomarkers ecosystem through extensive diagnostic portfolios, neuroimaging technologies, and large-scale clinical laboratory infrastructure.
Emerging Precision Diagnostics Players
- Quanterix Corporation
- Illumina Inc.
- Qiagen N.V.
These firms are expanding rapidly due to demand for blood-based biomarkers, genomic sequencing, and ultra-sensitive detection technologies for neurodegenerative diseases.
Research & Analytical Instrumentation Providers
- Agilent Technologies
- Bruker Corporation
- Bio-Rad Laboratories
- PerkinElmer
These companies primarily support biomarker discovery, translational neuroscience research, proteomics, and laboratory automation.
Integrated Life Sciences & Healthcare Conglomerates
- Danaher Corporation
- Merck KGaA
- Abbott Laboratories
- Sysmex Corporation
These firms strengthen the market through diversified diagnostic platforms, clinical testing capabilities, and pharmaceutical research support.
CNS Biomarkers Market Revenue Share and Offerings
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. is one of the leading players in the CNS biomarkers market with an estimated 2025 market revenue share of around 14%. The company focuses on neurology diagnostics, CSF biomarker testing, immunoassay platforms, and companion diagnostics for neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.
Thermo Fisher Scientific
Thermo Fisher Scientific accounts for nearly 11% of the CNS biomarkers market in 2025. The company offers advanced mass spectrometry systems, molecular diagnostics, sequencing technologies, and proteomics solutions widely used in neurological biomarker discovery and clinical research.
Bio-Rad Laboratories
Bio-Rad Laboratories holds an estimated 6% revenue share in the market. Its offerings include digital PCR platforms, multiplex immunoassays, protein analysis systems, and research reagents that support CNS disease biomarker identification and validation.
Quanterix Corporation
Quanterix Corporation captures around 5% of the CNS biomarkers market owing to its ultra-sensitive Simoa technology platform. The company specializes in blood-based neurological biomarker detection solutions for Alzheimer’s disease, traumatic brain injury, and other neurodegenerative conditions.
Siemens Healthineers
Siemens Healthineers contributes approximately 8% of the market revenue in 2025. Its portfolio includes advanced MRI and PET imaging systems, AI-enabled diagnostics, and laboratory testing solutions used for CNS disease detection and monitoring.
Abbott Laboratories
Abbott Laboratories represents nearly 7% of the CNS biomarkers market. The company provides immunodiagnostic analyzers, neurological biomarker assays, and point-of-care diagnostic systems that support early disease screening and monitoring.
GE HealthCare
GE HealthCare accounts for around 9% of the market share through its strong neuroimaging and molecular imaging portfolio. The company offers MRI, PET, and AI-driven imaging solutions that help in neurological disease diagnosis and biomarker assessment.
PerkinElmer
PerkinElmer holds an estimated 4% share in the CNS biomarkers market. Its offerings include biomarker discovery platforms, imaging systems, assay development technologies, and neuroscience research tools used in translational medicine.
Qiagen N.V.
Qiagen N.V. captures approximately 5% of the market with its genomic testing and molecular diagnostic solutions. The company provides PCR-based CNS diagnostic kits, liquid biopsy solutions, and neurogenetics research tools.
Agilent Technologies
Agilent Technologies accounts for nearly 5% of the CNS biomarkers market. The company specializes in chromatography systems, mass spectrometry instruments, and biomarker analysis software used in neurological research and proteomics studies.
Sysmex Corporation
Sysmex Corporation holds around 3% market share in 2025. The company offers laboratory diagnostics systems, immunochemistry platforms, and biomarker testing technologies supporting neurological disease diagnostics.
Danaher Corporation
Danaher Corporation represents approximately 8% of the CNS biomarkers market through its life sciences and diagnostics subsidiaries. The company provides molecular diagnostic tools, precision medicine platforms, and biomarker research technologies.
Merck KGaA
Merck KGaA accounts for nearly 4% of the market revenue. Its portfolio includes biomarker research reagents, cell analysis systems, and life science technologies that support CNS drug discovery and neurological biomarker research.
Illumina Inc.
Illumina Inc. captures around 6% of the CNS biomarkers market through its next-generation sequencing platforms and genomic profiling technologies. The company plays a major role in neurogenetic biomarker discovery and precision neurology applications.
Bruker Corporation
Bruker Corporation holds an estimated 5% share in the market. The company provides advanced mass spectrometry systems, neuroimaging research tools, proteomics platforms, and metabolomics solutions for CNS biomarker development.
Read Also: Dashboard Camera Industry Company Profiles & Competitive Analysis
Source: https://www.precedenceresearch.com/